Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for information titled “Content of Risk Information in the Major Statement in Prescription Drug Direct-to-Consumer Broadcast Advertisements [Docket No. FDA-2017-N-2936]” as published in the Federal Register on August 21, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS), the Centers for Medicare and Medicaid Services (CMS), and the Center for Medicare and Medicaid Innovation (CMMI) for the opportunity to provide comments in response to the request for information (RFI) titled “Centers for Medicare & Medicaid Services: Innovation Center New Direction” released on September 20, 2017.
Our organizations view medication-assisted treatment (MAT) as an important component of a multipronged approach to addressing opioid abuse and improving treatment. We applaud efforts to expand access to MAT, such as increasing Drug Addiction Treatment Act (DATA) waivered physician’s prescribing caps and allowing nurse practitioners (NPs) and physician assistants (PAs) to obtain a DATA waiver.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide input into the Texas Board of Pharmacy’s (Board) strategic planning process for fiscal years 2019-2023. As the profession of pharmacy continues to evolve and the role of pharmacists expand from dispensers of medications to direct care providers, so too must Board requirements.
The Academy of Managed Care Pharmacy (AMCP) thanks the Arkansas State Board of Pharmacy (Board) for the opportunity to provide comments on the proposed changes to Regulation 7 – Drug Products/Prescriptions as they relate to biosimilar products.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for comments titled “Administering the HatchWaxman Amendments: Ensuring a Balance Between Innovation and Access [Docket No. FDA–2017–N–3615]” as published in the Federal Register on June 22, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the solicitation of public comments on biosimilars included in the proposed rule “Medicare Program; Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2018 [Docket No. CMS-1676-P]” as published in the Federal Register on July 21, 2017.
AMCP joins a coalition of over 35 health care stakeholders committed to aligning 42 CFR part 2 (part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.
The Academy of Managed Care Pharmacy (AMCP) thanks the Institute of Clinical and Economic Review (ICER) for the opportunity to provide comments on the “Potential Topics for Review in 2018” released on July 26, 2017. AMCP applauds ICER for considering new and emerging therapies, as well as incorporating public feedback, into the development of a robust review agenda for 2018.
The Academy of Managed Care Pharmacy (AMCP) thanks the International Society for Pharmacoeonomics and Outcomes Research (ISPOR) for the opportunity to comment on the Draft Special Task Force Report “A Health Economics Approach to US Value Assessment Frameworks” as updated on July 7, 2017.
The Academy of Managed Care Pharmacy thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to comment on the Proposed Rule, Medicare Program; CY 2018 Updates to the Quality Payment Program (the Proposed Rule).
AMCP supports a coalition of over 20 health care stakeholders committed to aligning 42 CFR Part 2 (Part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.
